- Home
- BETR vs CLLS Comparison
BETR vs CLLS Comparison
Compare BETR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BETR | CLLS |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.8M | 394.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BETR | CLLS |
|---|---|---|
| Price | $13.55 | $2.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $40.00 | $8.33 |
| AVG Volume (30 Days) | ★ 677.0K | 14.3K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $164,872,000.00 | N/A |
| Revenue This Year | $55.02 | N/A |
| Revenue Next Year | $65.66 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 51.97 | N/A |
| 52 Week Low | $13.18 | $2.35 |
| 52 Week High | $94.06 | $5.48 |
Technical Indicators
Market Signals| Indicator | BETR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 58.70 |
| Support Level | N/A | $3.00 |
| Resistance Level | $28.72 | $3.40 |
| Average True Range (ATR) | 2.31 | 0.16 |
| MACD | -0.44 | 0.05 |
| Stochastic Oscillator | 1.89 | 91.57 |
Price Performance
Historical ComparisonAbout BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.